Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2024 - Issue 2

The Surprises of Molecular Testing in Neurofibromatosis Type 1: Rare Association between Two Mutational Variants Download PDF


, , , , ,
  1. Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.
  2. Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.
  3. Regional Center for Medical Genetics Bihor (part of ERN THACA), Bihor County Emergency Clinical Hospital, Oradea, Romania.
  4. Faculty of Medicine,” Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca Romania.
  5. Department II Medical Clinic, Faculty of Medicine, University” Lucian Blaga of Sibiu”, Sibiu Romania.
Abstract

Neurofibromatosis 1 (NF1 MIM # 162200) is one of the most prevalent illnesses that is inherited dominantly through autosomes. It is sometimes referred to as von Recklinghausen disease. The main features of this condition include neurocutaneous manifestations including café au lait spots, intertriginous freckling, different types of neurofibromas (cutaneous neurofibromas or plexiform tumors), neurological symptoms, and bone abnormalities. It happens at a rate of 1 in 3000 to 1 in 4000 occurrences. Cone-rod dystrophies are part of a diverse set of retinal dystrophies characterized by destruction to cone and rod cells, resulting in a wide range of clinical symptoms. Multiple genes contribute to the development of cone-rod dystrophy, with over 100 genes found so far. Among them is the CRX gene, which is linked to the autosomal dominant type of the condition. The authors describe a fascinating example of a patient diagnosed with Neurofibromatosis type 1 (NF1) as a baby, who developed myopia and astigmatism at age 15, leading to an unexpected outcome in molecular testing. A molecular DNA examination revealed the presence of two mutational variants: a pathogenic variant in the NF1 gene, c.3871-2A, and a possibly pathogenic variant in the CRX gene c.119G>A. The authors use this instance to demonstrate the unexpected findings from molecular testing in a disorder often diagnosed based on clinical criteria, offering patients expert genetic guidance.

Cite this article
Vancouver
Jurca A, Petchesi CD, Jurca MC, Bembea D, Jurca AD, Atasie D. The Surprises of Molecular Testing in Neurofibromatosis Type 1: Rare Association between Two Mutational Variants. Pharmacophore. 2024;15(2):70-8. https://doi.org/10.51847/QG2iHRJqUL
APA
Jurca, A., Petchesi, C. D., Jurca, M. C., Bembea, D., Jurca, A. D., & Atasie, D. (2024). The Surprises of Molecular Testing in Neurofibromatosis Type 1: Rare Association between Two Mutational Variants. Pharmacophore, 15(2), 70-78. https://doi.org/10.51847/QG2iHRJqUL

Related articles:
Most viewed articles:
QR code:

Short Link:
Views: 941

Downloads: 111
Quick Access

Associations

Pharmacophore
ISSN: 2229-5402

Copyright © 2024 Pharmacophore. Authors retain copyright of their article if they are accepted for publication.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.